SCHEMBL710154

SCHEMBL710154

COc1ccc(C=CC=Cc2ccccn2)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.55
RAB9A P51151 5/20 0.55
KDM4E B2RXH2 4/20 0.55
MAPT P10636 3/20 0.55
L3MBTL1 Q9Y468 2/20 0.55
MEN1 O00255 2/20 0.55
KMT2A Q03164 2/20 0.55
ALDH1A1 P00352 2/20 0.55
PKM P14618 1/20 0.55
TRPA1 O75762 1/20 0.55
CYP3A4 P08684 2/20 0.51
CYP1A2 P05177 1/20 0.51
CYP2D6 P10635 1/20 0.51
CYP2C9 P11712 1/20 0.51
HPGD P15428 1/20 0.51
CYP2C19 P33261 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
ATM Q13315 1/20 0.48
LMNA P02545 1/20 0.47
TP53 P04637 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL710153 1.00 NPC1 (0.55) NPC1RAB9AKDM4EMAPTL3MBTL1
SCHEMBL710300 0.90 MAPT (0.66) NPC1RAB9AKDM4EMAPTL3MBTL1
SCHEMBL710299 0.90 MAPT (0.66) NPC1RAB9AKDM4EMAPTL3MBTL1
SCHEMBL713803 0.83 RAB9A (0.48) NPC1RAB9AKDM4EMAPTL3MBTL1
SCHEMBL713804 0.83 RAB9A (0.48) NPC1RAB9AKDM4EMAPTL3MBTL1
SCHEMBL711201 0.83 NFE2L2 (0.56) MAPTCYP3A4CYP1A2CYP2D6CYP2C9
SCHEMBL711202 0.83 NFE2L2 (0.56) MAPTCYP3A4CYP1A2CYP2D6CYP2C9
SCHEMBL709611 0.81 MEN1 (0.54) NPC1RAB9AMAPTL3MBTL1MEN1
SCHEMBL709612 0.81 MEN1 (0.54) NPC1RAB9AMAPTL3MBTL1MEN1
SCHEMBL710225 0.80 NFE2L2 (0.52) NPC1RAB9AKDM4EMAPTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8124625-B2 enhancing the expression of apoAI; prevention or therapy of dislipidemia SHIONOGI & CO., LTD. (JP) 2012-02-28 US disclosed
US-8053445-B2 Utilities of olefin derivatives SHIONOGI & CO., LTD. (JP) 2011-11-08 US disclosed
US-20090036457-A1 Utilities of olefin derivatives YAMAMORI TERUO 2009-02-05 US disclosed
US-20040242615-A1 Utilities of olefin derivatives SHIONOGI & CO., LTD. (JP) 2004-12-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040242615-A1 Utilities of olefin derivatives APOL1, NR1H2, APOB NPC1 19/4885RAB9A 4723/4885KDM4E 4415/4885
US-20090036457-A1 Utilities of olefin derivatives APOL1, APOB, NR1H2 NPC1 48/4885RAB9A 4606/4885KDM4E 4647/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.